Bio-TCatTM Technology Viability Confirmed During Extensive Anellotech Pilot Plant Campaign

The viability of Anellotech’s Bio-TCat™ technology has now been proven by achieving commercially-targeted yields in its TCat-8® pilot unit in Silsbee, Texas during six months of continuous process operations.

Process yields of 22-24% by weight of liquid products from loblolly pine feedstock were demonstrated. Supplemental carbon monoxide (CO) output provides potential for an additional 3-5% yield by weight of cellulosic ethanol via third-party technologies or production of renewable electricity.

The Bio-TCat™ reactor produces a liquid product containing over 98% C6+ aromatic chemicals directly from the MinFree™-pretreated feedstock. After mild hydro-treating and purification, AnelloMate™ products – the family of liquid products made through Bio-TCat™ – meet all specifications for sale as chemicals or fuel blendstocks.

Anellotech is now planning the construction of its first commercial plant and is engaging in partnership and funding discussions with existing and new strategic partners. Engineering work is expected to begin this summer and once funding is secured, the next phase of construction will begin in the second half of 2020. The first plant will be capable of processing 500 bone dry tonnes/day of loblolly pine wood into 40,000 tonnes/year (860 BPSD) of products including benzene, toluene, xylenes, and C9+ aromatics to use as fuels or for making bio-based plastics for packaging and consumer products. 30,000 tonnes of carbon monoxide (CO) and other by-product gases will also be produced, for use in generating renewable electricity or used for chemical feedstock.

“We are delighted with these results, as they validate the economic potential of the Bio-TCat™ process and give us confidence that even small, initial scales of production are viable”, said David Sudolsky, President and CEO of Anellotech. “The goal of being cost-competitive with fossil resource technologies is a reality and we look forward to on-going process improvements.  

Anellotech and its partner Axens are looking forward to licensing much larger plants following this first commercialization. These would be five-times bigger, producing 200-250,000 tonnes/year (4,000-5,000 BPSD) of aromatics and 150,000 tonnes of CO. This rapidly expands the availability of bio-aromatics for chemicals and fuels, providing cost-competitive solutions needed by refiners and brand owners looking to make a difference in their carbon footprints.

“We are very excited about the prospects of deploying the Bio-TCat™ technology commercially under license in the coming years. We expect to bring non-food, renewable solutions to the fuels and chemicals markets for products that meet sustainability goals and provide attractive returns under competitive market conditions,” affirmed Pierre Beccat, Executive Vice-President Technology Development and Innovation at Axens.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Anellotech, Inc.. (2019, May 10). Bio-TCatTM Technology Viability Confirmed During Extensive Anellotech Pilot Plant Campaign. AZoCleantech. Retrieved on November 10, 2024 from https://www.azocleantech.com/news.aspx?newsID=26271.

  • MLA

    Anellotech, Inc.. "Bio-TCatTM Technology Viability Confirmed During Extensive Anellotech Pilot Plant Campaign". AZoCleantech. 10 November 2024. <https://www.azocleantech.com/news.aspx?newsID=26271>.

  • Chicago

    Anellotech, Inc.. "Bio-TCatTM Technology Viability Confirmed During Extensive Anellotech Pilot Plant Campaign". AZoCleantech. https://www.azocleantech.com/news.aspx?newsID=26271. (accessed November 10, 2024).

  • Harvard

    Anellotech, Inc.. 2019. Bio-TCatTM Technology Viability Confirmed During Extensive Anellotech Pilot Plant Campaign. AZoCleantech, viewed 10 November 2024, https://www.azocleantech.com/news.aspx?newsID=26271.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.